Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2020
Reporting Period: Event date August 3, 2020; Signed August 7, 2020
Context: The Company entered into a Settlement Agreement and General Release (SAGR) with ChubeWorkx Guernsey Limited to terminate a prior 2016 agreement that granted ChubeWorkx a security interest in substantially all of the Company's assets.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The following specific financial obligations were disclosed:
- Cash Settlement: $300,000 payable to ChubeWorkx.
- Equity Settlement: 500,000 shares of Common Stock issued to ChubeWorkx.
- Potential Liquidated Damages: 1.0% of the market value of the Shares payable monthly if registration requirements are not met by specified deadlines.
- Debt/Liquidity: The filing does not provide current debt levels or liquidity metrics, but notes the termination of a prior security interest in Company assets.
Material Changes
The primary material change is the resolution of a prior encumbrance on the Company's assets:
- Termination of Prior Agreement: The 2016 Settlement Agreement, which granted ChubeWorkx a security interest in substantially all Company assets, has been terminated.
- Issuance of Securities: 500,000 shares of unregistered common stock were issued to ChubeWorkx under Section 4(a)(2) and Regulation D exemptions.
- Shareholder Support: ChubeWorkx entered into a "Leak-Out and Support Agreement," agreeing to vote the new shares in favor of matters proposed by the Board of Directors.
Guidance, Risks, and Contingencies
Contingencies and Risks:
- Registration Risk: The Company must file a resale registration statement for the 500,000 shares by August 18, 2020, and have it declared effective by the earlier of October 2, 2020, or 45 days after filing.
- Penalty Risk: Failure to meet the registration deadlines triggers monthly cash payments equal to 1.0% of the market value of the Shares until compliance is achieved.
- Legal Finality: The SAGR is intended to fully and finally settle all current and future claims between the Company and ChubeWorkx related to the prior agreements.
Management Commentary: The filing contains no forward-looking guidance regarding revenue or operational outlook. The transaction is described as an inducement to settle claims and remove the security interest on assets.
Investor Verification Checklist
- Verify the current market price of AKER stock to calculate the potential monthly liquidated damages (1% of share value) if registration deadlines are missed.
- Confirm the filing status of the resale registration statement for the 500,000 shares issued to ChubeWorkx.
- Review the full text of the Settlement Agreement (Exhibit 10.1) to understand any remaining covenants or conditions not summarized in the 8-K.
- Assess the impact of the $300,000 cash outflow on the Company's current cash position.